CEL-SCI (NYSEMKT:CVM) is up 4% premarket on modestly higher volume in reaction to its announcement that its Phase 3 clinical trial
evaluating MultiKine (leukocyte interleukin, injection), combined with
chemo agent cyclophosphamide, NSAID indomethacin and zinc in a
multivitamin combo prior to radiotherapy, in head and neck cancer
patients will continue unchanged until the requisite number of events
(deaths) have occurred for the primary endpoint of overall survival.
Secondary endpoints include progression-free survival and quality of life measures.
The estimated completion date is December per ClinicalTrials.gov.
MultiKine is mass-produced biologic containing 14
natural human cytokines designed to boost the immune response to cancer.
The company is developing the immunotherapy as a neoadjuvant to be
administered right after diagnosis and before surgery.
https://seekingalpha.com/news/3505750-cel-sci-4-percent-premarket-continuation-phase-3-multikine-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.